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1. Zusammenfassung 
 
Einleitung:  
 
Brustkrebs ist weltweit die häufigste Krebserkrankung bei Frauen. Insgesamt hat sich 
die Prognose für die Betroffenen in den letzten 30 Jahren deutlich verbessert. Gründe 
dafür sind zum einen eine verbesserte Prävention, zum anderen neuartige 
therapeutische Möglichkeiten wie die Behandlung mit monoklonalen Antikörpern.  
Trotz dieser Fortschritte ist die Prognose für Patienten mit metastasierten Tumoren 
nach wie vor ungünstig und die Therapie der metastasierten Krebsformen immer noch 
eine Herausforderung. 
 
Die Forschung der letzten Jahre hat gezeigt, dass das Tumor umgebende Stroma eine 
entscheidende Rolle für das Tumorwachstum im Ursprungsgewebe, aber auch für die 
Metastasenbildung und das Überleben der disseminierten Tumorzellen in 
ursprungsfernen Organen spielt. 
Der Einfluss von Fettgewebe als endokrin aktives Organ auf Brustkrebs wurde in 
verschiedenen Studien untersucht. Allerdings ist bisher unklar, welche Rolle 
mesenchymale Stammzellen aus dem Fettgewebe für die Metastasierung von 
Brustkrebszellen spielen. 
In der vorliegenden Arbeit wurde der Einfluss dieser Zellen auf die Invasivität muriner 
und humaner Brustkrebszellen untersucht und versucht, molekulare therapeutische 
Ziele zu identifizieren, um den Metastasierungsprozess zu reduzieren.  
 
Methodik:  
 
Der Einfluss mesenchymaler Stammzellen auf Brustkrebszellen wurde mit Hilfe von  
Proliferations-, Invasions-Assays und zweidimensionalen direkten Kokulturen 
untersucht. Mediatoren, die für diese Interaktion eine Rolle spielen könnten, wurden 
mit ELISA, Zymographie, Immunohistochemie und RT-PCR identifiziert. Um die 
Zusammenfassung	   	  5	  
Relevanz des gefundenen Signalmoleküls für die Invasion zu evaluieren, wurde ein 
neutralisierender Antikörper eingesetzt. 
 
Ergebnisse:  
 
Humane Brustkrebszellen induzieren eine de novo Sekretion des Chemokines CCL5 
(RANTES) in mesenchymalen Stammzellen und dieses steigert wiederum die Anzahl 
der invasiven Brustkrebszellen um 126%. Weitere Experimente zeigen, dass CCL5 die 
Sekretion der Matrixmetalloproteinase 9 in mesenchymalen Stammzellen steigert. 
 
Schlussfolgerung:  
 
Es konnte gezeigt werden, dass mesenchymale Stammzellen aus dem Fettgewebe 
einen signifikanten Einfluss auf die Invasivität muriner und humaner Brustkrebszellen 
haben. Das Chemokin CCL5 (RANTES) ist in diesem Zusammenhang verantwortlich 
für den proinvasiven Effekt und kann mithilfe eines neutralisierenden Antikörpers 
blockiert werden.  
Weitere Studien mit in-vivo Tumormodellen können wichtige Hinweise zur Rolle dieser 
Stammzellen in der gesamten Tumorgenese liefern. Weiterhin sollte CCL5 (RANTES) 
als therapeutisches Ziel bei Brustkrebspatienten evaluiert werden. 
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2. Summary 
 
Introduction:  
 
Breast cancer is the leading form of cancer in women worldwide. Overall the prognosis 
for those patients has improved in the last 30 years. This is due to improved prevention 
and new therapeutic approaches like monoclonal antibody treatments.  
However, the treatment of metastatic breast cancer remains challenging not only in 
breast cancer but all kinds of disseminating cancers. Therefore the prognosis for 
patients with metastases is still poor. 
 
During the last decades of cancer research it became clear that the tumor stroma plays 
a crucial role in primary tumor growth, metastatic progression, and survival of 
disseminated tumor cells in distant organs. The influence of adipose tissue as an 
endocrine organ on breast cancer has been investigated in some studies. However it is 
still elusive what role adipose tissue derived stem cells (ASCs) play in breast cancer 
metastasis. 
 
The present study investigates the effect of ASCs on the invasion of murine and 
human breast cancer cells and tries to identify candidate signaling molecules that 
might be therapeutic targets in metastatic breast cancer patients. 
 
Methods:  
 
The effect of ASCs on breast cancer cells has been studied with proliferation assays, 
invasion assays and 2-dimensional direct co-cultures. Molecules involved in this 
interaction have been measured with ELISA, Zymography, Immunohistochemistry and 
RT-PCR. To evaluate the relevance of the identified molecules, neutralizing antibody 
has been used. 
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Results: 
  
We could show that human breast cancer cells induce a de-novo secretion of CCL5 
(RANTES) in ASCs which then acts in an invasion promoting as well as paracrine 
manner on breast cancer cells (126% increase in number of invasive breast cancer 
cells).  
Furthermore we found that CCL5 might induce a higher secretion of matrix 
metalloproteinase 9 in ASCs. 
 
Conclusion:  
 
Taken together, our results indicate that adipose tissue derived stem cells promote 
breast cancer cell invasion in a CCL5 (RANTES) dependent manner. A CCL5 
neutralizing antibody could block the invasion promoting effect.  
 
Further investigation with in-vivo models is necessary to clarify the role of CCL5 in 
breast cancer progression, and in order to evaluate the potential relevance of ASCs 
and CCL5 as therapeutic targets in breast cancer patients. 
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3. Abbreviations 
 
 
AB  Antibody 
AB-Ag complex  Antibody-antigen complex 
ASCs  Adipose tissue-derived stem cells 
BSA Bovine serum albumin 
cDNA  Complementary deoxyribonucleic acid 
DAPI 4',6-diamidino-2-phenylindole 
DiI 1,1',di-octadecyl-3,3,3'3'- 
 tetramethylindocarbocyanine perchlorate 
DiO 3,3'-dioladecyloxacarbocyanine perchlorate 
DMEM/F12  Dulbecco modified Eagle's minimal essential  
 medium/F12 
DNA  Deoxyribonucleic acid 
ELISA  Enzyme-linked Immunosorbent assay 
FBS  Fetal bovine serum 
FITC  Fluorescein isothiocyanate 
GAPDH  Glycerine aldehyde-3-phosphate dehydrogenase 
GFP Green fluorescent protein 
H2O  Water 
hASC Human Adipose tissue-derived stem cells 
HBSS  Hankes’ balanced salt solution 
HMEC Human mammary epithelial cells 
IBC Inflammatory breast cancer 
MRI Magnetic resonance imaging 
LABC Locally advanced breast cancer 
mASC Murine adipose tissue-derived stem cells 
MEM α1  Minimal essential medium alpha modification 
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mg  Milligram(s) 
ml  Milliliter(s) 
MMP Matrix metalloproteinase 
P  Passage 
PBS  Phosphate buffered saline 
PCR  Polymerase chain reaction 
PFA Paraformaldehyde 
RANTES Regulated upon Activation, Normal T-cell  
 Expressed, and Secreted 
RNA  Ribonucleic acid 
rpm  Rotations per minute 
RT Room temperature 
RT-PCR Real-time polymerase chain reaction 
SCCM Stem cell conditioned medium 
TCM Tumor conditioned medium 
VEGF Vascular endothelial growth factor 
µg  Microgram(s) 
µl  Microliter(s) 
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4. Introduction 
 
EPIDEMIOLOGY 
Breast cancer is the most common cancer in women worldwide and represents 23% of 
all cancers. In 2002 an estimated number of 1.15 million patients were diagnosed with 
breast cancer. Furthermore breast cancer is, despite having a generally rather good 
prognosis, one of the leading causes of cancer death in women (Jemal et al., 2008; 
Parkin et al., 2005).  
Globally, the rates of breast cancer incidence vary. The highest rates are found in 
North America and northern Europe, whereas the lowest rates are observed in Asia 
and Africa. Reasons for these differences could be different genetic backgrounds as 
well as the corresponding environmental and biological circumstances that affect risk 
factors involved in facilitating the outgrowth of breast cancer (Parkin et al., 2005). 
Studies taking into consideration migration patterns consistently indicated that the 
incidence of breast cancer increases from generation to generation in migrant 
populations, thus supporting the hypothesis of societal factors influencing rates of 
breast cancer (Willett et al., 2004). 
 
Interestingly, the mortality of breast cancer has been declining constantly since 1975 
despite a significant rise of breast cancer incidence in the early 1980s, which was most 
likely due to the newly established mammography and its successful introduction as a 
diagnostic tool for screening purposes. This new technique, together with the use of 
aggressive adjuvant chemotherapies, led to the overall decrease in breast cancer 
mortality (Berry et al., 2005).  
 
However, the management of the metastatic progression in breast cancer, as well as in 
other cancer types, remains extremely challenging due to lack of knowledge about the 
cellular and molecular components of this pathological process. Therefore, the five 
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year survival rates for the more aggressive subtypes of breast cancer such as locally 
advanced and inflammatory breast cancer range according to the lymph node status 
after neoadjuvant therapy from 20% to 30% (Buzdar et al., 1995). 
RISK FACTORS 
Various risk factors have been identified as relative contributors to the increased 
incidence of breast cancer. Age and gender are among the strongest risk factors, 
followed by factors such as genetics, personal history, benign breast disease, ethnicity 
and lifestyle, hormonal, and environmental factors. These different parameters add up 
to a multifactorial and personal risk profile that needs to be evaluated individually for 
each patient. 
 
Interestingly body weight as a risk factor for breast cancer is controversially discussed 
since a high premenopausal body mass index (BMI) has been correlated with a lower 
breast cancer incidence (van den Brandt et al., 2000), whereas postmenopausal 
obesity is associated with a higher breast cancer risk (Ahn et al., 2007). In the latter 
case, adipose tissue as a converter of estrogen precursors to estrogen seems to be 
most likely explanation. However, the complex role of adipose tissue in breast cancer 
as a highly active endocrine organ remains elusive. 
SYMPTOMS 
Most patients in Western countries are diagnosed because of abnormal mammograms 
and do not show specific symptoms related to breast cancer at the time of diagnosis. 
Nevertheless, breast cancer also has a typical pathological manifestation that can be 
evaluated by means other than mammography.  
Patients with locally advanced breast cancer (LABC, 30 to 50% in medically 
underserved populations) and inflammatory breast cancer (IBC, 0.5 to 2 % of invasive 
breast cancer) especially have a characteristic clinical presentation (Ezzat et al., 1999; 
Hance et al., 2005). 
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Different visual and haptic signs can indicate the development of breast cancer. 
Palpable and in some cases visible indurations are present, along with local pain and 
an increasingly tender, firm and enlarged breast. A spontaneous clear or bloody 
discharge from the nipple is often associated with a breast lump, along with the 
retraction or indentation of the nipple or any flattening or indentation of the skin over 
the. Further examination of the skin might show a warm and thickened “peau d’orange” 
(skin of an orange) with an alteration in color from pink to redness, or a purplish hue in 
case of IBC. Signs of LABC and IBC include a fixation of the breast to the chest wall, 
fixed or matted axillary nodes, or ipsilateral satellite skin nodules (Robertson et al., 
2010). 
DISEASE PROGRESSION 
Breast cancer can arise from different cell types associated with the mammary gland 
and is therefore divided into the following molecular subtypes of breast cancer: basal-
like, luminal A, luminal B, HER2+/ER- and normal breast-like. Natural history of breast 
cancer involves the progression from ductal hyperproliferation to subsequent ductal 
carcinoma in situ (DCIS), invasive carcinoma, and finally metastatic disease.  
 
According to the angiogenic and angioinvasive properties of the tumor cells, they also 
invade lymphatic vessels and furthermore form so-called tumor emboli, which are 
responsible for both the local signs and symptoms as described above, and for the 
lethal development of distant metastases.  
 
The organs most commonly affected by breast cancer metastases are bone, liver, lung, 
and brain, in this order. Secondary organ failure finally leads to exitus. Therefore, 
patients with metastatic breast cancer disease have the worst outcome and are 
unlikely to be treated in such a way that complete remission is achieved (Greenberg et 
al., 1996). 
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DIAGNOSIS 
The leading diagnostic tool for breast cancer is mammography. Once a suspect 
radiologic correlate of breast malignancy has been detected, several diagnostic 
adjuncts to mammography are available. In order to differentiate between cystic and 
solid masses, ultrasound examination of the breast can provide important evidence.  
 
Contrast-enhanced breast magnet resonance imaging (MRI) might prove as an 
ultimately better but also more expensive diagnostic test as compared to the 
ultrasound, since it provides the clinician with more accurate diagnostic information in 
patients where mammography and ultrasound cannot give clear results. 
 
Finally, different techniques of biopsy such as surgical biopsy, fine needle aspiration 
biopsy, or core biopsy are available in order to gain more details about histologic 
composition of suspect lesions, and thus can provide important information to aid in 
designing the optimal individual treatment (Winchester et al., 2000). 
PROGNOSIS 
The overall prognosis of breast cancer is good due to well established screening 
methods, improvement in surgical intervention, and new approaches in combined 
chemotherapies.  
However, the prognosis is dependent on the presence of prognostic factors such as 
age and menopausal status, tumor stage and histologic grade, clinical response, 
hormone receptor status, and lymph node status following induction (also termed 
neoadjuvant) therapy, the latter being most important for prognostic estimations. 
 
In general, the prognosis for patients worsens according to the invasiveness of the 
breast cancer type. The study of Smart showed an average decrease in 20-year 
survival rate of nearly 30 percent when comparing In situ-breast cancer patients to 
lymph node positive invasive breast cancer patients (Smart et al., 1997). 
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TUMOR-STROMA INTERACTION IN BREAST CANCER PATHOLOGY 
In the last decades, the concept of cancer changed in a way that cells which are not 
cancer cells per se turned out to be promising targets for cancer therapy since it 
became clear that the tumor microenvironment plays a crucial role in both primary 
tumor growth and metastatic spread. Although the “seed and soil” theory had already 
been developed in 1889 by Paget (Paget, 1989), the complex interplay of cancer cells 
and stromal or circulating cells leaves many unanswered questions. 
 
The transformation from individual, polarized, structurally organized, quiescent 
epithelial cells anchored in extracellular matrix, to highly motile, matrix-digesting breast 
cancer cells capable of invading vessels, travelling with the circulation, and 
extravasating vessels at distant organ sites, is an extremely complex transformation.  
 
This malignant progression, common to all lethal cancerous diseases, becomes even 
more intriguing when considering that invasive breast cancer cells, once present in 
their main metastatic targets such as bone, liver, and lung, need to recruit and 
manipulate local cells in order to initiate remodeling of extracellular matrix, release of 
different growth factors, and neovascularization to support the colonization of other 
organs and enable the outgrowth of metastases. 
 
Another interesting approach to the cancer disease is the comparison of cancer with a 
“never healing wound” (Schafer and Werner, 2008). Recent studies outlined the 
parallels between the processes that occur during wound healing and the progression 
from a locally restricted tumor to a metastatic disease. Both require the crosstalk 
between epithelial cells and stromal cells and involve a wide variety of cytokines and 
matrix molecules. 
 
Chemokines have been characterized for their myriad of functions in inflammatory 
processes,  especially leukocyte chemotaxis and proliferation, but also hematopoiesis, 
cell-virus interactions, angiogenesis, neovascularization, and tumor metastasis 
(Allavena et al., 2008a; Homey et al., 2002; Balkwill, 2003; Challita-Eid et al., 1998). 
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The family of chemokines includes about 50 different members subdivided into groups 
according to their chemical structure. 
 
CCL5, formerly known as RANTES (Regulated on Activation, Normal T-cell Expressed 
and Secreted), belongs to the group of CC–Chemokines (Fig.1) and has become more 
and more interesting in the last ten years of breast cancer research for its strong pro-
migratory effects as well as its function as a strong chemoattractant for inflammatory 
cells to wounds or tumor sites (Wigler et al., 2002; Eissa et al., 2005; Yaal-Hahoshen 
et al., 2006; Soria and Ben-Baruch, 2008).  
 
CCL5, located on chromosome 17, is a β-chemokine and binds to three different G-
protein linked transmembrane receptors (CCR1, CCR3 and CCR5), with CCR5 being 
the main receptor.  
 
Several pathways activated by CCL5 subsequently enhance the expression of cell 
migratory effector molecules and also induce the transcription of molecules involved in 
the inflammatory signaling cascade (van Deventer et al., 2008; Ben-Baruch, 2008; 
Youngs et al., 1997; Mueller et al., 2006; Luo et al., 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
In the process of invasion and metastasis, not only the chemotactic molecules play an 
important role for tumor and stromal cell mobilization and homing, but also enzymes 
Fig. 1 Concept of chemical 
structure of CC-motif Chemokines. 
The position of the first two 
cysteines in the N-terminal part of 
the protein defines the group of 
chemokines (Ali and Lazennec, 
2007) 
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that degrade the extracellular matrix and thus might contribute to the release of 
sequestered factors that promote angiogenesis such as VEGF (Du et al., 2008; Zhao 
et al., 2008; Luo et al., 2006; Chabottaux and Noel, 2007).  
 
Furthermore, they enable tumor cells to migrate through basement membranes in the 
context of intra- and extravasation. These enzymes are mostly 
matrixmetalloproteinases (MMPs). Two well-characterized MMPs responsible for 
digesting collagen IV, a major component of the basement membrane, are MMP-9 and 
MMP-2 (Figueira et al., 2009; Sun et al., 2009; Gonzalez et al., 2008). 
 
Together with intrinsic alterations in the cancer cell comes an alteration in the tumor 
microenvironment. It has been shown that cytokines and chemokines are responsible 
for the recruitment of leukocytes to the tumor site (Mantovani et al., 2004).  
 
We hypothesized that in breast cancer, the surrounding fat tissue, which contains 
multipotent stem and progenitor cells, might be used by tumor cells to create the 
inflammatory environment that eventually facilitates the transition towards malignancy, 
specifically by orchestrating an extracellular matrix structure and milieu that enhances 
processes like leukocyte recruitment, neovascularization, tumor cell invasion, and 
intravasation. 
 
We carried out a series of candidate approach experiments in order to determine 
whether and how adipose tissue derived stem cells might be involved in the secretion 
of CCL5 and MMP-9. 
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4.1 Aim of the study 
The aim of this study was to investigate whether tissue resident stem cells from the 
adipose tissue might play a role in breast cancer metastasis. Recent studies have 
shown that the process of breast cancer metastasis is significantly influenced by the 
surrounding tumor stroma and circulating cells. In order to elucidate the role of tumor-
adjacent multipotent stem cells possibly representing early tumor response cells, we 
performed a series of experiments as shown in the flow chart of experiments (Fig. 5).  
The main focus of this study was to evaluate the significance of human adipose tissue 
derived stem cells (hASCs) on breast cancer cell invasion and to identify mediators 
involved in the interaction of hASCs and breast cancer cells. 
 
Therefore, we defined the following questions in the indicated order: 
 
1) What is the effect of hASCs on breast cancer cell invasion in vitro? 
 
2) What role does the chemokine CCL5 (RANTES) play in this context? 
 
3) Is the matrixmetalloproteinase 9 (MMP-9) involved? 
 
In addition, we wanted to elucidate whether there is a direct link between the de novo 
secretion of CCL5 and the upregulation of MMP-9. 
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5. Materials and Methods 
5.1 Materials	  
5.1.1 Animals 
Balb/c mice, 6-8 weeks Ingeneron, Houston, TX, USA 
5.1.2 Cells 
 
Cell line/ cell type Abbreviation Transfection Source 
Human Adipose tissue 
derived stem cells 
hASC -- Established from patients 
undergoing elective liposuctions 
Murine adipose tissue 
derived stem cells 
mASC -- Established from subcutaneous and 
kidney capsule fat of Balb/c mice 
Murine breast cancer 
cells 4T1 
4T1 -- ATCC, Manassas, VA, USA 
GFP-labeled murine 
breast cancer cell line 
4T1 
GFP-4T1 EGFP ATCC, Manassas, VA, USA 
Human breast cancer 
cell line MDA MB 231 
MDA MB 231 -- ATCC, Manassas, VA, USA 
GFP-labeled human 
breast cancer cell line 
MDA MB 231 
GFP-MDA 
MB 231 
EGFP ATCC, Manassas, VA, USA 
Human breast cancer 
cell line MCF-7 
MCF-7 -- Oesterreich Lab, Baylor College of 
Medicine, Houston, TX, USA 
Human embryonic 
fibroblast WI-38 
WI-38 -- Hung Lab, MDACC, Houston, TX, 
USA 
Immortalized Human 
mammary epithelial 
cells 
HMEC Immortalized 
with 
Telomerase 
and SV40 
large T- 
antigen 
Weinberg Lab, Whitehead Institute, 
Boston, MA, USA 
Table 1 Cell types 
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5.1.3 Tissue Culture 
α-MEM Mediatech Inc, Herndon, VA, USA 
RPMI   Mediatech Inc, Herndon, VA, USA 
L-15 Leibovitz  HyClone Lab., Inc., l South Logan, UT, USA 
DMEM  Mediatech Inc, Herndon, VA, USA 
Fetal bovine serum Atlanta biologicals, Lawrenceville, GA, USA 
Penicillin/Streptomycin Mediatech Inc, Herndon, VA, USA 
L-Glutamin Mediatech Inc, Herndon, VA, USA 
Trypsin-EDTA Sigma, St. Louis, MO, USA 
Hanks’ balanced salt solution (1X) Mediatech Inc, Herndon, VA, USA 
Dulbecco’s Phosphate-buffered saline (1X) Sigma, St. Louis, MO, USA 
Liberase Blendzyme 3 Roche Diagnostics, Indianapolis, IN, USA 
Culture flasks T25, T75, T175 Greiner Bio-One, Monroe, NC, USA 
Centrifuge tubes 15ml, 50ml Greiner Bio-One, Monroe, NC, USA 
6-well plate Greiner Bio-One, Monroe, NC, USA 
	  
5.1.4 Cell staining 
Paraformaldehyde (Fixation) Sigma, St. Louis, MO, USA 
DiI Invitrogen Corporation, Carlsbad, CA, USA 
DIO Invitrogen Corporation, Carlsbad, CA, USA 
DAPI Invitrogen Corporation, Carlsbad, CA, USA 
Goat-serum Sigma, St. Louis, MO, USA 
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5.1.5 Antibodies 
Anti-human RANTES Antibody R&D Systems, Inc., Minneapolis, MN, USA 
Normal Goat IgG Control Antibody R&D Systems, Inc., Minneapolis, MN, USA 
Rabbit anti-human CCR-5 Antibody Abcam Inc., Cambridge, MA, USA 
Goat anti-rabbit IgG (H+L) Invitrogen Corporation, Carlsbad, CA, USA 
	  
5.1.6 Assays and Kits 
Invasion Chambers BD Biosciences, Bedford, MA, USA 
Quantikine ELISA CCL5, TNFα  R&D Systems Inc., Minneapolis, MN, USA 
Interleukin-6 (human) EIA Kit Assay Designs, Ann Arbor, MI, USA 
SYBR-Green Master Mix Applied Biosystems, Foster City, CA, USA 
RNAqueous®-Micro Kit Applied Biosystems, Foster City, CA, USA 
iScript cDNA Synthesis Kit Bio-Rad Laboratories, Hercules, CA, USA 
	  
5.1.7 Antibiotics 
 Puromycin Sigma, St. Louis, MO, USA 
	  
5.1.8 Zymography 
Zymogram (Gelatin) Gel Invitrogen Corporation, Carlsbad, CA, USA 
Prestained Protein ladder Invitrogen Corporation, Carlsbad, CA, USA 
Renaturing buffer Invitrogen Corporation, Carlsbad, CA, USA 
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Developing buffer Invitrogen Corporation, Carlsbad, CA, USA 
	  
5.1.9 Real-Time PCR 
Primer Sigma, St. Louis, MO, USA 
DNAse/RNAse free water Invitrogen Corporation, Carlsbad, CA, USA 
BlueJuice gel loading buffer Invitrogen Corporation, Carlsbad, CA, USA 
Agarose gel (UltraPure) Invitrogen Corporation, Carlsbad, CA, USA 
	  
5.1.10 Plasmid 
plox/EW-iRES-EGFP Tronolab, Lausanne, CH 
	  
5.1.11 Chemicals 
	  
Ethanol Sigma, St. Louis, MO, USA 
DMSO Sigma, St. Louis, MO, USA 
Trypan Blue Sigma, St. Louis, MO, USA 
Bovine Serum Albumin (BSA) Sigma, St. Louis, MO, USA 
Antibody Diluent Invitrogen Corporation, Carlsbad, CA, USA 
Ethidium bromide Sigma, St. Louis, MO, USA 
Recombinant human CCL5  Sigma, St. Louis, MO, USA 
Polybrene Infection/ Transfection Reagent Millipore, Billerica, MA, USA 
Coomassie Blue Sigma, St. Louis, MO, USA 
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5.1.12 Equipment 
Centrifuge, Model 5682 Forma Scientific Inc., Marietta, OH, USA 
Steri-Cult Incubator Forma Scientific Inc., Marietta, OH, USA 
ChemiImager (Zymography) Alpha Innotech Corp., San Leandro, CA, USA 
Digital camera Canon, Lake Success, NY, USA 
Hemacytometer Hausser Scientific, Horsham, PA, USA 
Axiovert 25 (microscope) Zeiss, Thornwood, NY, USA 
Axiovert S100 (Fluorescence microscope) Zeiss, Thornwood, NY, USA 
 
Cool SNAP cf (Camera) Photometrics, Tucson, AZ, USA 
µ-Quant (Plate-Reader) Bio-Tek Instr. Inc., Highland Park, VT, USA 
i-Cycler (RT-PCR) Bio-Rad Laboratories, Hercules, CA, USA 
x-cell Sure Lock (Zymography) Invitrogen Corporation, Carlsbad, CA, USA 
FACSVantage SE cell sorter Becton–Dickinson, Franklin Lakes, NJ, USA 
	  
5.1.13 Software 
NIS-elements BR Nikon Instruments Inc., Melville, NY, USA 
ImageJ http://rsb.info.nih.gov/ij/ 
SPSS (Version 16) SPSS Science, Chicago, IL, USA 
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5.2 Cell biology methods 
 
5.2.1 Isolation and culture of adipose tissue derived stem cells 
(ASCs) 
 
5.2.1.1 murine ASCs 
Murine adipose tissue derived stem cells were obtained from Balb/c mice (InGeneron, 
Inc.) following the guidelines of Veterinary Medicine & Surgery of the MD Anderson 
Cancer Center. The procedures were carried out at InGeneron Inc., Houston, TX. For 
primary culture of murine adipose tissue derived stem cells regular α-MEM 
supplemented with 20% FBS, penicillin (100 U/ml), 100 µg/ml streptomycin and 0.3 
mg/ml L-Glutamin. 
PROTOCOL 
Each mouse was sacrificed by carbon dioxide inhalation. After performing a 
longitudinal cut from the umbilical area to the ventral neck, skin was further dissected 
without disturbing the muscular fascia. Subcutaneous fat was scratched off, collected 
in a sterile petri-dish, humidified with PBS and put on ice until digestion. The fat tissue 
was furthermore harvested from the renal capsules after opening the abdominal cavity. 
The collected fat mass was weighed and minced with a razor blade to less than 1 mm3 
pieces in a petri dish. Samples were processed from this step on as described above 
for human adipose tissue.  
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5.2.1.2 human ASCs 
Adipose tissue was obtained from patients undergoing elective liposuction (Fig 2). After 
isolation, cells were grown in regular α-MEM supplemented with 20% FBS, penicillin 
(100 U/ml), 100 µg/ml streptomycin and 0.3 mg/ml L-Glutamin. 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
 
PROTOCOL 
After its weight was recorded, the fat tissue was washed with sterile Phosphate 
buffered saline (PBS) and subsequently minced thoroughly into pieces of less than 1 
mm3. The minced tissue was incubated with Dulbecco’s Phosphate-buffered saline (10 
ml per gram fat) containing two units Blendzyme 3 per gram fat for 30 minutes at 37 °C 
on a shaker at 50 rpm. Thereafter the suspension was disaggregated by pipetting it 
through a 25 ml serological glass pipette 10 times under sterile conditions. The 
incubation procedure was repeated for 10 minutes followed by pipetting. After a total 
digestion time of approximately 30 minutes the processed tissue was transferred into 
50 ml plastic tube, followed by centrifugation at 1500 rpm for 10 minutes and 3 washing 
Fig.	  2	  a)	  Human	  fat	  obtained	  during	  surgical	  liposuction	  and	  processed	  for	  isolation	  of	  ASCs.	  b)	  Human	  fat	  
tissue	  after	  digestion,	  filtration	  and	  centrifugation	  steps.	  The	  pellet	  contains	  the	  target	  cells	  which	  were	  
subsequently	  cultured	  in	  T75-­‐Flasks	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steps with phosphate buffered saline (PBS). The cell pellet was resuspended in PBS 
and subsequently filtered through a 100 µm vacuum filtration system. The filtered cell 
suspension was then centrifuged at 1500 rpm for 10 minutes followed by two washing 
steps with PBS. The pelleted cells were resuspended in growth medium consisting of 
alpha  modification of Eagle’s medium (α-MEM), 20 % fetal bovine serum (FBS), 2 mM 
L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin. Plastic adherent adipose 
tissue derived stem cells (ASCs) were grown in cell culture flasks (Fig. 3) at 37 °C in a 
humidified atmosphere containing 5 % CO2. Daily washings removed red blood cells 
and non-attached cells. Three to five days later, ASCs were plated in tissue culture 
flask at a density of 1,000 cells/cm2. 
	  
	  
	  
	  
	  
	  
	  
	  
 
 
 
 
 
 
Fig.	  3	  Human	  adipose	  
tissue	  derived	  stem	  cells	  
in	  culture.	  Phase	  contrast	  
picture	  of	  hASCs	  at	  
passage	  3,	  brightfield	  and	  
10x	  magnification	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5.2.2 Cell freezing and thawing 
To maintain a stock of each cell line, 106 cells/freezing vial were stored in a liquid 
nitrogen tank. 
PROTOCOL 
Cells to be stored were trypsinized, counted and centrifuged at 1400 rpm for 5 minutes. 
The cell pellet was then resuspended in freezing medium (FBS containing 10% 
DMSO).  1 ml of freezing medium and 106 cells was pipetted into freezing vials and 
stored for 24h at -70oC.  After 24h at -70oC freezing vials were transferred to the liquid 
nitrogen tank. 
To thaw cells, the specific cell-culture medium had been preheated in a T75 flask in the 
incubator. The freezing vial was warmed to 37oC after being removed from the nitrogen 
tank and complete content was transferred into 37oC warm medium of T75 flask. 
Medium was changed 24h after thawing procedure. 
5.2.3 Labeling of cells 
 
5.2.3.1 GFP-labeling  
To clearly identify the counted cells on the lower surface of invasion assay 
membranes, cells were either labeled with green fluorescent protein (GFP), DiI or DiO. 
Nuclei were stained with DAPI. 
PROTOCOL (GFP-LABELING) 
MDA MB 231 cells or 4T1 cells respectively grown in bulk (in T75 flasks) for 2 weeks 
were detached by trypsin-EDTA treatment and replated in 6-well plates at a density of 5 
x 104 cells in 2 ml of α-MEM (MDA MB 231) or RPMI (4T1) per well. Transductions with 
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a plox/EW-iRES-EGFP lentivirus were carried out in the presence of 8 µg of Polybrene 
per ml. After incubation at 37°C for 24 h, the transduction medium was replaced with 
fresh α- MEM (RPMI respectively). The cells were kept for 3 more weeks with medium 
changes at weekly intervals before FACS analyses were done. After 3 weeks GFP-
positive cells were analyzed and sorted using FACSVantage SE cell sorter. GFP-
positive cells were sub cultured in α-MEM/RPMI (both 10% FBS) until used for invasion 
assays. 
5.2.3.3 DiI, DiO and DAPI staining 
 
PROTOCOL (DII)  
Cells that were 80% confluent in a T25 flask were incubated at 37oC in 5% CO2 with 
3ml of their regular Culture-Medium, containing 15 µl of DiI (Dilution of DiI 1/200) for 
1h. In the next step cells were washed 2x with PBS, before regular medium was added 
for a 5 minutes incubation time. This step was repeated and cells were then harvested 
and seeded for the following experiment. 
PROTOCOL (DIO) 
The procedure applied was analogue to the one described for DiI-Staining. 21µl of DiO 
stock solution were diluted in 3 ml of corresponding culture medium. 
 
PROTOCOL (DAPI) 
Cells were fixed with 4% PFA (Volume was adapted to experimental setting) for 10 
minutes at room temperature. After rinsing 2x with PBS cells were exposed to a 1/1000 
diluted DAPI solution (1µl of DAPI stock solution in 1 ml of PBS) for 15 min at room 
temperature protected from light. Cells were rinsed again and pictures were taken. 
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5.2.3.3 Immunostaining 
The cells subject to immunostaining were seeded in a density of 3 to 5 x 104 in 12-well 
plates. The staining procedure was carried out according to the following protocol: 
1. Washing of cells twice with PBS. 
2. Adding of 4 % paraformaldehyde for 10 min at RT. 
3. Washing of cells twice with PBS. 
4. Adding of serum blocking solution (10% goat serum), incubation at RT for 10 
minutes 
5. Adding of primary antibody (dilution 1:100 in antibody diluent), incubation at  
37 oC for 1 hour, or incubation overnight at 4 oC 
6. Washing of cells twice with PBS. 
	  
The following steps were carried out in the dark. 
	  
7. Adding of secondary antibody (dilution 1:1000 in antibody diluent); incubate at 
37 oC in moist chamber for 40 minutes 
8. Washing of cells twice with PBS. 
9. Adding of DAPI  (Dilution of 1:1000 in PBS), incubation at RT for 15 mins 
10. Washing of cells twice with PBS. 
	  
Cells were viewed under the fluorescent microscope and pictures were taken at a 
10/20 fold magnification. 
5.2.4 Conditioning of medium 
Media of hASCs or MDA MB 231 were conditioned to elucidate whether humoral 
factors secreted by the cells would induce CCL5 secretion in other cell lines. 
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PROTOCOL 
Cells were seeded in 6-well plates at a confluence of 40-50% in 5% FBS containing 
medium. After 48h the medium was harvested, centrifuged at 1500 rpm for 5 minutes. 
The supernatant was passed through  a Millipore sterile 50 mL filtration system with a 
0.45-µm polyvinylidene difluoride membrane. Conditioned medium was stored at -20oC 
until used for ELISA or Proliferation Assay. Conditioned medium from MDA MB 231 
cells (Tumor-conditioned medium, TCM) or from hASCs (stem cell conditioned 
medium, SCCM) was also used to stimulate other cell lines for 48h before stored at -
20oC and analyzed with ELISA. 
5.2.5 Proliferation Assay 
To see whether the milieu created by hASCs provides a proliferation friendly 
environment for MDA MB 231 cells a proliferation assay was conducted by 
documenting viable cell numbers over four days in the control group and the treatment 
group respectively. 
PROTOCOL 
104 MDA MB 231 cells were seeded in 6-well plates in 2 ml of MEM (10% FBS). After 
24h medium was exchanged to MEM (5% FBS) in the control group and to stem cell 
conditioned medium (conditioning time 48h) in the treatment group. Cell number and 
viability was assessed after day 1, day 2, day 3 and day 4 with Trypan Blue exclusion 
test. 
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5.2.6 Direct co-culture Assay 
Breast cancer cells (MDA MB 231/MCF-7) were given the possibility to interact directly 
with stromal (hASCs/WI-38) or epithelial cells (HMECs). The supernatant of direct co-
cultures was used for chemokine/interleukin analysis by ELISA. 
PROTOCOL 
After washing cells with PBS they were digested with Trypsine and counted. Breast 
cancer cells and stromal/epithelial cells were always seeded at a ratio of 1:2 
(BCC:stromal/epithelial cell).  When seeded in a  6-well plate the absolute seeding 
number for Breast cancer cells was 5x104 and for stromal/epithelial cells 105 per well. 
5.2.7 Invasion Assay 
In order to assess the ability of cells to invade extracellular matrix, Boyden Chamber 
Invasion assays were used. The membranes of the inserts were covered with Matrigel 
(main components being laminin and collagen IV) and thus represent a valuable tool to 
evaluate invasion in vitro which can be correlated to metastatic behavior of tumor cells 
in vivo. 
PROTOCOL 
The chemoinvasion assay was performed using Boyden chambers with filter inserts 
(pore size, 8 µm) coated with Matrigel in 24-well dishes (BD Biosciences Bedford, MA) 
according to the manufactures instructions. Before performing the invasion assay, cells 
were mixed together in 5% FBS containing MEM when seeded in co-culture. 
Approximately, 3 x 104 cells or 6 x 104 cells respectively were placed in 600µl of 5% 
FBS containing MEM in the upper chamber, and 750µl  of the same medium containing 
10% FBS was placed in the lower chamber. The plates were incubated for 48 h at 370C 
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in 5% CO2. Cells on the upper side of the filters were removed with cotton-tipped 
swabs, and the filters were rinsed with PBS. Cells on the lower side of the filters were 
examined and counted under a microscope. Fluorescent cell signal of GFP/DiI/DAPI-
labeled 4T1 or MDA MB 231 cells was counted in five randomly chosen view fields at a 
10x magnification of every insert (Fig 4).  
 
 
	  
	  
	  
	  
	  
	  
	  
	  
	  
5.2.8 CCL5 treatment  
Breast cancer cells (MDA MB 231) and hASCs were stimulated with human 
recombinant CCL5 in different concentrations to see whether CCL5 induces a higher 
expression of MMP-2 /MMP-9 both on mRNA and active protease level. 
 
 
Fig.	  4	  	  a)	  Insert	  and	  24-­‐well	  plate	  containing	  medium	  as	  used	  for	  invasion	  assays.	  b)	  Schematic	  
illustration	  of	  invasion	  assay	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PROTOCOL 
Cells were grown in 6-well plates to 70-80% confluence.  When the experiment was 
started, medium was changed to 5% MEM containing 1ng/ml, 5ng/ml, 10ng/ml, 
20ng/ml and 100ng/ml of recombinant human CCL5. Cells were incubated at 37oC, 5% 
CO2 and 95% humidity for 1h, 2h and 48h. At the end of the treatment, medium was 
harvested, centrifuged at 1500 rpm for 5 minutes and supernatant-aliquots stored at -
20oC until used. Cells in each well were counted (Trypan Blue) and either disposed or 
used for RNA extraction. 
5.3 Molecular biology methods 
 
5.3.1 ELISA 
 
Enzyme-linked Immunosorbent assay is a common and widely used technique 
designed for detecting and quantitating substances such as peptides, proteins, 
antibodies, antigens and hormones. 
The plate surface is coated with an antibody (capture antibody) which specifically binds 
to one particular type of protein. After adding the sample to the plate, the proteins of 
interest adhere to the antibody-coated surface. In the next step, detection antibody 
specific to the protein of interest is added to all wells. The detection antibody binds to 
the capture antibody-linked proteins; any unbound detection antibodies are removed by 
a subsequent washing step. Thereafter, a secondary enzyme-conjugated antibody is 
added which recognizes the detection antibody. In the final step, a substrate is added 
and converted by the antibodylinked enzyme to a detectable form. In order to quantify 
the sample proteins, the generation of a standard curve with known protein 
concentration is required which is typically a serial dilution of the protein. Protein 
concentration of CCL5/IL-6/TNFα in the supernatant of cell cultures was achieved by 
ELISA according to the manufacturer’s protocol. 
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5.3.2 RNA extraction 
 
In order to evaluate the mRNA levels of different genes of interest under different 
conditions, RNA was extracted from cells, transcribed into cDNA stored at -200C and 
subsequently used for real-time PCR analysis.  
PROTOCOL 
Total RNA was extracted from hASCs and MDA MB 231 after CCL5 treatment for 1h, 
2h, and 4h using RNAqueous kit (Applied Biosystems) according to the manufacturer’s 
instructions. The final concentration of RNA was determined with a spectrometer at 
wavelengths of 260 nm and 280 nm.  
The RNA was then used right away for subsequent reverse transcription into 
complementary DNA (cDNA) or stored at -80oC. 
5.3.3 cDNA synthesis 
The extracted total RNA was reverse transcribed into cDNA using iScript cDNA 
Synthesis Kit according to the manufacturer’s instructions. The added amount of RNA 
was standardized between samples to the concentration of 1 µg/µl. 
	  
Component	   Total	  volume:	  20	  µl	  
RNA	   x	  µl	  
Reaction	  mix	   4	  µl	  
Reverse	  transcriptase	   1	  µl	  
RNA	   y	  µl	  
 
x	  =	  volume	  of	  RNA	  that	  equals	  1	  µg	  after	  
measuring	  conc.	  with	  spectrometer	  
y	  =	  volume	  of	  water	  	  
to	  add	  reaction	  volume	  up	  to	  20	  µl	  
Table 2 cDNA reaction mix 
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PROTOCOL 
The complete reaction mix was incubated using following cycles with the iCycler 
(BioRad): 5 minutes at 25oC, 30 minutes at 42oC, 5 minutes at 85oC, and kept at 4oC 
until stored at -20oC and subsequently used for real-time PCR. 
5.3.4 Real time PCR 
Detection of gene transcripts in MDA MB 231 and hASCs was determined by qRT-
PCR (quantitative real time polymerase cheain reaction). All samples were prepared 
and quantified as described above. mRNA expression level was determined with RT-
PCR using SYBRGreen assay according to manufacturer’s instructions. 12.5 µl of the 
assay reaction mix, 1 µl of each primer (Table 2) and 1 µl of cDNA were mixed with 
water to a total volume of 25 µl and placed into BioRad PCR cycler. For relative 
quantification,  
glycerinaldehyde-3-phosphate-dehydrogenase (GAPDH) served as reference and data 
were analyzed according to Pfaffl method.  
The sequences (5’-3’) for the primers were the following: 
	   GAPDH-forward  5’- GAA GGT GAA GGT CGG AGT C -3’ 
 GAPDH-reverse  5’- GAA AGA TGG TGA TGG GAT TTC -3’ 
 MMP-2-forward  5’- TGGCGATGGATACCCCTTT -3’ 
 MMP-2-reverse  5’- TTCTCCCAAGGTCCATAGCTCAT -3’ 
 MMP-9-forward  5’- CCTGGGCAGATTCCAAACCT -3’ 
 MMP9-reverse  5’- GCAAGTCTTCCGAGTAGTTTTGGAT -3’ 
 CCR-5-forward  5′-CAAAAAGAAGGTCTTCATTACACC-3′  
 CCR-5-reverse  5′-CCTGTGCCTCTTCTTCTCATTTCG-3′ 
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5.3.5 Zymography 
In order to detect catalytically active MMP-9 and MMP-2 respectively zymography was 
performed with supernatants of cell cultures. 
 
PROTOCOL 
 
MMP-9 and MMP-2 activity was determined using a 10% zymogram (gelatin) precast 
gel (Invitrogen cat no. EC6175). Preparation of cell lines was conducted by seeding the 
appropriate amount of cells (50 000) into each respective well of a 6-well plate. Cells 
were cultured at 37oC (5% CO2 atmosphere) until 80% confluency. Upon confluence 
media was changed to serum-free media and cells were cultured for an additional 48 
hours. After 48 hours conditioned media was collected and mixed with equal volumes 
of 2X SDS (15 µl conditioned media: 15 µl 2X SDS). (Note: Preparation of conditioned 
media was not heated or reduced for detection of MMP-9 activity using zymography). 
The electrical running apparatus was then prepared containing the 10% zymogram 
(gelatin) pre-cats gel and 1X running buffer (12g Tris, 57.6g Glycine, 10% SDS, 4l 
distilled water). Samples were then loaded accordingly (15 µl Invitrogen pre-stained 
protein ladder-cat no. 10748010) into the 10% zymogram (Gelatin) pre-cat gel and 
allowed to run at room temperature at 125V for 1.5 hours. After electrophoresis the 
zymogram gel was removed and incubated (30 minutes with gentle agitation) at room 
temperature in a zymogram renaturing buffer (1:9 with deionized water). Upon 
incubation, the renaturing buffer was decanted and further incubated at room 
temperature in 1X developing buffer (1:9 with deionized water) for 30 minutes. After 30 
minutes the developing buffer was then decanted and replaced with fresh developing 
buffer. After equilibration with fresh developing buffer the zymogram gel was allowed to 
incubate overnight at 37oC. After overnight incubation the developing buffer was 
decanted and replaced with coomassie staining solution (25% MeOH, 10% Acetic Acid, 
and 0.1% Coomassie Brillant Blue-dissolved in water before adding) for two hours at 
room temperature. Upon staining the zymogram gel was destained (10% Acetic acid, 
15% MeOH) at room temperature using gentle agitation. Once destained the 
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zymogram gel was photographed (ChemiImager 5500) to determine the areas of 
protease activity (clear bands). 
5.4 Statistical analysis 
Data are presented as means ± standard deviation (SD). Analysis was performed 
using the Statistical Program for Social Science (SPSS) for Windows (SPSS Inc., 
Chicago, IL, USA).  A level of p ≤ 0.05 was considered to be statistically significant. 
5.5 Flow chart of experiments 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
The experimental outline to address the questions standing in the focus of this work is 
shown in Figure 5.  
Fig.	  5	  Flowchart	  of	  experiments	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6. Results 
 
6.1  Proliferation of MDA MB 231 cells in stem cell 
conditioned medium (SCCM) 
As a starting point to investigate the interaction of adipose tissue derived stem cells 
and breast cancer cells the effect of soluble factors secreted by hASCs on the 
proliferation of the human breast cancer cell line MDA MB 231 was studied. Therefore 
5% FBS containing cell culture medium (α-MEM) of human ASCs was conditioned for 
48h and MDA MB 231 cells were exposed to the conditioned medium to evaluate their 
growth rate in this environment in order approach the question whether and how 
hASCs interact with MDA MB 231 cells. 
104 cells/well of MDA MB 231 cells were seeded in a set of 6-well plates and exposed 
either to stem cell conditioned medium (SCCM) or to regular 5% FBS containing α-
MEM as a control. 
The factors secreted by the hASCs had no negative impact on the growth rate of the 
MDA MB 231 cells. Notably a higher proliferation rate could be observed in the group 
with SCCM compared to the control group with regular growth medium on day four 
(Fig. 6). 
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6.2 ASCs increase invasiveness of breast cancer 
cells 
To characterize the effect that mesenchymal stem cells derived from the adipose tissue 
exert on the invasive behavior of breast cancer cells invasion assays were performed. 
One murine breast cancer cell line (4T1) and two human breast cancer cell lines (MCF-
7 and MDA MB 231) differing in their invasive behavior (MCF-7 cells tend to be less 
invasive than MDA MB 231 cells) were seeded alone or together with ASCs on 
matrigel coated membranes imitating extracellular matrix. The matrigel on the chamber 
Fig. 6 Stem cell conditioned medium enhances proliferation of MDA MB 231. 
MDA MB 231 cells were grown in 6-well plates. The SCCM group was 
exposed to stem cell conditioned medium (hASCs). The control was exposed 
to regular growth medium containing 10 % FBS. The SCCM group shows a 
higher proliferation at day 4. * P < 0.05, n.s. not significant. 
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membranes mainly contains Laminin (56%), Collagen IV (31%) and Entactin (8%). 
Therefore cells attempting to migrate through this membrane have to secrete 
extracellular matrix digesting enzymes like Matrixmetalloproteinase 2 (MMP-2) and 
MMP-9 besides of being stimulated to migrate. 
Following a gradient from 5% FBS containing medium (upper chamber) to 10% FBS 
containing medium (lower chamber) the cells had to degrade the matrigel to invade 
towards the lower surface of the membrane.  Initially a roughly doubling of invasive 
murine breast cancer cells could be detected. To see whether the observed effect in 
the context of murine cells interacting with murine adipose-tissue derived stem cells 
also applies for human cells a series of invasion assays was performed to elucidate the 
effect of hASCs on MCF-7 and MDA MB 231 cells. In parallel invasion assays were 
carried out with 24h, 36h and 48h incubation time. It turned out that an incubation time 
of 48h for the murine cell lines and 36h for the human cell lines represented the ideal 
time frame to evaluate the difference in number of invasive cells. The ratio between 
seeded breast cancer cells and additional cell line (hASCs, WI-38 or HMECs) was kept 
at 1:2 for all experiments. 
	  
6.2.1 mASCs and 4T1 
3x104 GFP-labeled 4T1 cells and 6x104 non-labeled mASC (Passage 2-4) were seeded 
on the upper surface of a matrigel coated membrane to evaluate the number of 
invasive cells without any further conditions. After 48h the non invasive cells were 
scrubbed off the upper surface by using a moistened q-tip. The remaining cells were 
counted under the microscope in five randomly chosen view fields at a 10x 
magnification. With the overlay of the brightfield image and the GFP-Signal it could be 
confirmed that the GFP-Signal clearly correlates with the cells and is not an artifact of 
the membrane (Fig. 7). 
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To evaluate the effect of mASCs (6x104) on 4T1 (3x104) invasion the two different cell 
lines were co-seeded on the same membrane. After removing again the non-invasive 
cells only the GFP-Signal was counted in five view fields (Fig.8). Co-seeding lead to an 
increase of 137 % of invasive 4T1 cells (27.6 ± 6.98 as compared to 11.6 ± 5.12 per 
view field). 
 
 
Fig.7 Murine adipose tissue derived stem cells promote GFP-4T1 breast cancer cell 
invasion. Pictures a,d,g show the matrigel coated membrane with the indicated cells 
seeded on the surface after 48h incubation time before scrubbing off the non-invasive 
cells. a) 6 x 104 mASCs, d) 3 x 104 GFP-labeled 4T1, g) 3 x 104 GFP-labeled 4T1 
coseeded with 6 x 104 mASCs. Pictures b,e,h show the membranes after removing all 
non-invasive cells. b) mASCs, e) GFP-4T1, h) GFP-4T1 with mASCs. Pictures c,f,i show 
the GFP-Signals of invasive GFP-labeled 4T1 cells. 
. 
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6.2.2 hASCs and MCF-7 
5x104 DiI-labeled MCF-7 cells alone and 5x104 DiI-labeled MCF-7 cells together with 
105 hASCs (Passage 2-4) were seeded on the Matrigel surfaces. After removing all 
non-invasive cells the nuclei of all invasive cells on the lower surface of the 
membranes were counterstained with DAPI. 
Since MCF-7 is a less invasive breast cancer cell line and tends to grow in an epithelial 
cell like manner it was not possible to clearly identify single cells. Therefore, the visual 
impression of an increase in invasive number of MCF-7 cells could not be quantified as 
for the 4T1 and MDA MB 231 cells. 
Fig.8 Coseeding of GFP-4T1 and mASCs resulted in 2.38 fold higher number of 
invasive GFP-4T1 cells as compared to seeding 4T1 cells alone.  Results are 
expressed as the mean ± SD. *P < 0.005 
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Interestingly, the staining of the nuclei with DAPI revealed that a lot more cells were 
invasive than the DiI (MCF-7) staining showed alone (Fig. 9) indicating that hASCs 
have a strong invasive capacity.  
	  
 
 
 
 
 
 
 
7.2.3 hASCs and MDA MB 231 
 
 
With the MDA MB 231 human breast cancer cell line we chose one of the most 
invasive and metastatic cell lines that have been established. Therefore these cells  
represent a powerful source to study mechanisms of invasion in vitro and in vivo. 
MDA MB 231 alone (3x104/insert) or MDA MB 231 (3x104/insert) together with hASCs 
(6x104/insert) were seeded on the matrigel surfaces. Furthermore, two more non-
tumorigenic  cell lines were coseeded with MDA MB 231 cells to elucidate whether the 
observed effect is indeed due to hASCs or simply a result of a higher seeding density. 
The human embryonic lung fibroblast cell line WI-38 has been used as control for the 
mesenchymal cell type and the immortalized human mammary epithelial cell line 
HMEC has been used as control for the epithelial cell type (Fig.10). 
Remarkably the increase in invasive breast cancer cells could be only observed when 
MDA MB 231 cells were given the possibility to interact with hASCs (105 ± 16.97 as 
Fig.9 hASCs promote invasion of MCF-7. Coseeding of MCF-7 along with hASCs resulted in 
more DiI labeled MCF-7 colonies on the lower surface of invasion chambers. a,b,c,d show 
different stainings and overlay of MCF-7 cells alone. e,f,g,h show different stainings of MCF-
7 coseeded with hASCs. The dye is indicated above each column. 
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compared to 46.4 ± 21.54). Whereas there was no increase in invasive MDA MB 231 
cells when seeded together with WI-38 or HMEC cells (Fig. 11). 
 
 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
 
 
 
 
 
 
 
Fig.10 Human adipose 
tissue derived stem cells 
promote invasion of MDA 
MB 231.  
a) Brightfield image of MDA 
MB 231  (35 x 103 cells) 
seeded on matrigel of 
invasion chamber.  
b) Phase contrast image of 
matrigel after scrubbing the 
upper surface with a cotton 
swab to remove all non-
invasive cells.  
c) GFP signal of invaded 
MDA MB 231 cells.  
d) Overlay of b) and c).  
e) Green signal shows 
invaded GFP-MDA MB 231 
when coseeded with 
hASCs.  
f) Green signal shows 
invaded GFP-MDA MB 231 
when Co-Cultured with 
hASCs in the presence of 
neutralizing CCL5-antibody 
(3µg/ml).  
g) Green signal shows 
invaded GFP-MDA MB 231 
when coseeded with WI-38 
cells.  
h) Green signal shows 
invaded GFP-MDA MB 231 
when coseeded with 
HMECs.  
The seeding ratio was 
always 1:2 (GFP-MDA MB 
231 : hASCs/WI-
38/HMEC). 
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To exclude that the alteration of invasive behavior is associated with the cell staining 
procedures the invasion assays for the MDA MB 231 series was carried out with GFP-
labeled MDA MB 231 cells as well as with DiI-labeled MDA MB 231 cells. The invasion 
promoting effect of hASCs on MDA MB 231 cells could be observed in a similar pattern 
in both conditions. 
	  
	  
	  
	  
	  
	  
	  
	  
	  
 
 
 
6.3  MDA MB 231 induce de-novo secretion of 
CCL5 (RANTES) in hASCs 
In order to identify potential mediators of the interaction between breast cancer cells 
and ASCs the chemokine CCL5 (RANTES) has been measured with ELISA as a 
candidate mediator that has been shown to be involved in breast cancer metastasis. 
Fig.11 Coseeding of GFP-MDA MB 231 and hASCs resulted in 2.26 fold higher number 
of invasive GFP-MDA MB 231 cells as compared to seeding GFP-MDA MB 231 cells 
alone. The CCL5 neutralizing antibody blocked the invasion promoting effect of hASCs. 
WI-38 and HMECs did not show the invasion promoting effect as compared to hASCs. 
Quantitative data of invaded GFP-MDA MB 231 cells per view field is shown as mean ± 
SD. * P<0.005, n.s. not significant. 
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Therefore breast cancer cells, ASCs or control cell lines have been seeded in systems 
of direct co-cultures in 6-well plates as shown below. 
 
 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
 
Figure 12 shows a direct co-culture of MDA MB 231 cells and hASCs (Passage 4). 
Both cell lines were labeled either with DiI (red, MDA MB 231) or DiO (green, hASCs) 
respectively prior to seeding cells. Before taking the pictures all cells were 
counterstained with DAPI (blue, nuclei). In the lower row starting from the left the 
brightfield picture, overlay of DAPI, DiI and DiO and the overlay of all is shown. The 
MDA MB 231 showed a regular distribution between the hASCs without building 
colonies of cancer cells. 
 
 
 
 
Fig.12 Direct Co-Culture of MDA MB 231 and hASCs. 5 x 104 DiI-MDA MB 231 (red) cells 
were seeded together with 105 hASCs (Passage 4, green) in 6-well plates. After 48h 
incubation direct Co-Cultures were fixed and nuclei were stained with DAPI (blue) before 
taking pictures. 
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Figure 13 shows a direct co-culture of MCF-7 cells and hASCs (Passage 4). Both cell 
lines were labeled as described above for the co-culture of MDA MB 231 and hASCs. 
In the lower row starting from the left the brightfield picture, overlay of DAPI, DiI and 
DiO and the overlay of all is shown. The MCF-7 formed round shaped islands of cancer 
cell colonies without penetrating the hASCs. The hASCs organized themselves around 
those islands. 
Interestingly these two human breast cancer cell lines seem to differ not only in their in 
vitro invasion capacity but also in their way of organizing in a direct co-culture with 
hASCs. The MDA MB 231 cells deriving from the more invasive cell line as compared 
to the MCF-7 cell line showed a more equal distribution of individual breast cancer cells 
between the hASCs. Whereas the MCF-7 cells did not leave their source colony and 
thus formed growing islands of monolayer breast cancer cells surrounded by hASCs 
indicating that signaling between these cell lines affects the growth pattern of hASCs in 
a specific way according to their invasive capacity. 
Fig.13 Direct Co-Culture of MCF-7 and hASCs. 5 x 104 DiI-MCF-7 (red) cells were seeded 
together with 105 hASCs (Passage 4, green) in 6-well plates. After 48h incubation direct Co-
Cultures were fixed and nuclei were stained with DAPI (blue) before taking pictures. 
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6.3.1 CCL5 is produced in direct co-culture of hASCs and 
breast cancer cells 
The concentration of CCL5 was measured in the supernatants of cell culture by 
harvesting the medium, centrifuging it at 1,500 rpm for 5 min and the supernatant was 
passed through a Millipore sterile 50 mL filtration system with a  0.45-µm polyvinylidene 
difluoride membrane. 
CCL5 could only be detected in the supernatants of the direct co-culture, whereas 
MDA MB 231 alone and hASCs alone did not produce any CCL5, highlighting this 
chemokine as potential target for further investigation (Fig.14a). By measuring the 
timepoints of 12h, 24h, 36h, 48h, 60h and 72h the kinetics of the chemokine showed a 
plateau starting between the 60h and the 72h timepoints (Fig. 15a). 
Furthermore there was no CCL5 detectable by exposing the MDA MB 231 cells to 
direct WI-38 contact (Fig. 15b). Interestingly CCL5 could be measured in the cell 
culture of HMEC and in the Co-Culture of HMEC together with MDA MB 231 (data not 
shown). 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Fig.14 a) CCL5 is produced by hASCs when exposed to tumor conditioned medium (MDA MB 
231) or in direct Co-Culture with MDA MB 231. All conditions were analyzed with ELISA after 
48h incubation.  b) CCL5 is produced by MCF-7 cells and not significantly more in direct Co-
Culture with hASCs. All columns without error bars indicate that no CCL5 was detectable with 
ELISA. 
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When measuring the supernatants of MCF-7 cultures a baseline level of CCL5 was 
secreted by MCF-7 cells. In contrast to the direct Co-Culture of MDA MB 231 with 
hASCs no induction of CCL5 secretion could be observed in the MCF-7/hASCs – direct 
co-cultures (Fig. 14b). 
From this point on we focused on the interaction of MDA MB 231 cells and hASCs 
since only in this context CCL5 was induced in hASCs in such a dramatic manner. 
6.3.2 Humoral MDA MB 231 derived factors induce CCL5 
secretion in hASCs 
To answer the question which cell line would be responsible for the CCL5 secretion the 
conditioned media of both hASCs and MDA MB 231 cells were used to stimulate the 
counterpart respectively (Fig. 16). 
 
 
Fig.15  a) Secretion kinetics of CCL5 in direct Co-Culture of MDA MB 231 and 
hASCs. b) hASCs exposed to tumor conditioned medium (MDA MB 231) was used as 
a control for this ELISA. Heat denaturation of TCM (MDA MB 231) eliminated the 
humoral factors secreted by MDA MB 231 cells to stimulate hASCs. CCL5 was not 
detectable in supernatants of WI-38 cell culture and direct Co-Culture of MDA MB 231 
and WI-38 cells. 
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CL5 was markedly high produced only by hASCs (Fig. 14a) after exposing them to  
tumor conditioned medium (TCM) while the MDA MB 231 cells did not secrete any 
CCL5 after being incubated with stem cell conditioned medium (SCCM). 
In order to see whether the humoral factors secreted by MDA MB 231 cells were 
proteins by nature, the TCM had been heat denatured before being used for hASCs 
stimulation. In this case there was no CCL5 measurable any more (Fig 15b). 
6.4 The CCL5-receptor CCR5 is expressed by 
both hASCs and MDA MB 231 
The main receptor for CCL5 is CCR5 and has been shown to play a pivotal role in the 
interaction of breast cancer cells and bone-marrow derived mesenchymal stem cells. 
Fig.16 Scheme of cross conditioning. Green (TCM) and yellow (SCCM) arrows indicate 
transfer of tumor conditioned medium (TCM) and stem cell conditioned medium (SCCM) to 
the according cell line as indicated. Red circles mark secretion of CCL5. 
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Therefore the expression of CCR5 (hASCs, MDA MB 231) as well as the exposure of 
the receptor on the cell surface has been investigated with RT-PCR and 
Immunohistochemistry (Fig. 17 and Fig. 18) respectively. 
 
 
 
 
 
 
 
 
 
 
 
RT-PCR for CCR5 was performed by using GAPDH as reference gene. The mRNA 
expression levels of the two cell lines relative to GAPDH for the CCL5 (RANTES) 
receptor CCR5 were calculated as shown below. The mRNA expression of CCR5 in 
MDA MB 231 was 40.09 fold higher as compared to hASCs in Passage 4. The relative 
expression was calculated according to the formula below. 
1) Expression (∆CT) = CT(target gene) - CT(reference gene) 
2) relative Expression = 2-∆∆CT[∆CT(MDA MB 231) - ∆CT(hASCs)] 
Figure 17 and 18 show DAPI staining for the nuclei, the red signal shows CCR5 on the 
cell surface and the overlay shows the association of receptor and nuclei staining for 
MDA MB 231 and hASCs as indicated. 
Interestingly both the cancer cell line MDA MB 231 and the hASCs showed a regular 
pattern of CCR5 on the cell surface. This shows that CCL5 has the possibility to bind to 
its main receptor on MDA MB 231 cells and hASCs. Following this insight the role of 
CCL5 in the context of enhanced invasion in the interaction of MDA MB 231 cells and 
hASCs needed to be clarified. 
Fig.17 Immunostaining (MDA MB 231) for CCR5.  
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6.5 CCL5 is necessary to promote invasion of 
MDA MB 231 
With CCL5 being secreted by hASCs only after being stimulated by humoral tumor 
derived factors the question arose whether CCL5 is involved in the promotion of MDA 
MB 231 invasion. Therefore the invasion assays have been repeated with additionally 
incubating the cells in the coseeding with a neutralizing CCL5 antibody. 
These invasion assays showed that adding the CCL5 antibody blocked the invasion 
enhancing effect of hASCs on MDA MB 231 (Fig. 10f). To exclude the possibility that 
random binding of the antibody was responsible for reducing MDA MB 231 invasion the 
control IgG antibody has been incubated during the invasion assays as well and did not 
show any alteration in MDA MB 231 invasive behavior. 
 
Fig.18 mRNA 
expression of 
CCR5 in MDA 
MB 231 and 
hASCs and 
Immunostainin
g (hASCs) for 
CCR5. 
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6.6 MMP-9 is a candidate protease contributing 
to higher invasion of MDA MB 231 
To further characterize the consequences of hASCs interacting with MDA MB 231 cells 
several zymographies have been carried out. Zymography is a valuable method to 
evaluate the production of certain enzymes and at the same time to see their 
enzymatic activity. In this case two candidate proteases have been looked at, 
Matrixmetalloproteinase-2 (MMP-2/Gelatinase A) and Matrixmetalloproteinase-9 
(MMP-9/Gelatinase B). 
 
6.6.1 MMP-9 activity is upregulated in direct co-culture of 
hASCs and MDA MB 231 
The settings for measuring the MMP-9/MMP-2 activity were the same as described 
above. MDA MB 231 (5 x 104 cells/well) and hASCs (105 cells/well) were seeded alone 
or together in direct co-culture (ratio of MDA MB 231 to hASCs was as before 1:2). The 
supernatants containing active MMP-2/MMP-9 were harvested as mentioned before 
and either directly used directly for zymography or stored at -20 oC until use. 
 
 
 
 
 
 
 
 
 
Fig.19 MMP-9 activity in 
MDA MB 231 and 
hASCs Co-Culture. 
MMP-9 activity was 
analyzed with a pre-cast 
(Gelatin) Zymogram gel. 
Lanes show clear bands 
of MMP-9 activity. 
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Notably after 36 and 48 hours there was a significant increase of active MMP-9 in the 
supernatants of the direct co-culture (Fig. 19). MMP-2 did not show any change in 
activity when MDA MB 231 cells were interacting with hASCs. The differences between 
bands of active Enzyme activity were confirmed by measuring the average density with 
the Software Image J. 
 
	  
	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 20 Quantitative data of MMP-9 activity. The correlating bands of the zymography 
gel are displayed above each column. *P< 0.05 compared to hASCs cultured alone at 
48 hours. 
	  
Results	   	  54	  
6.6.2  CCL5 does not increase MMP-9 Activity in MDA MB 231 
but in hASCs 
With CCL5 and MMP-9 being upregulated in the supernatants of MDA MB 231 and 
hASCs co-cultures we wanted to answer the question whether MMP-9 might be a 
downstream effector molecule of CCL5. Since we already found that MMP-9 and MMP-
2 are higher expressed on the RNA level of MDA MB 231 after being stimulated for 2h 
with human recombinant CCL5 in a pilot experiment (data not shown) we wanted to 
confirm this observation on the level of enzyme activity by zymography (Fig. 21). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the direct co-culture of MDA MB 231 and ASCs the highest activity of MMP-9 was 
detected between 36h and 48h. To determine the role of CCL5 in this context MDA MB 
231 were stimulated with CCL5 for 48h and the activity of MMP-9 and MMP-2 in the 
supernatants was analyzed by zymography. 
Fig.21 MMP-9 and MMP-2 activity of 
MDA MB 231 and hASCs after 
stimulation with recombinant human 
CCL5. Concentrations of CCL5 were 
applied as indicated above each 
condition. 
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The activity of neither MMP-2 nor MMP-9 was markedly altered in the treated MDA M 
231 cells as compared to the control group. However the activity of MMP-9 seemed to 
be lower in the 1ng/ml group (average density 96.37 ± 6.384 as compared to 144.809 ± 
24.603 in the control group). 
Interestingly the zymography of hASCs  stimulated with CCL5 also showed a lower 
average density in the 1ng/ml group (107.941 ± 16.224 as compared to 120.972 ± 
24.814 in the control group) but a higher average density in the 100 ng/ml group 
(146.147 ± 36.882 as compared to 120.972 ± 24.814 in the control group). 
6.7 Summary of Results 
Taken together the results can be summarized as the following: 
1) Adipose tissue derived stem cells (ASCs) promote breast cancer cell 
invasion in vitro 
2) Humoral tumor derived factors stimulate ASCs to produce CCL5 (RANTES) 
3) CCL5 plays a pivotal role in promoting breast cancer cell invasion in vitro 
4) MMP-9 is up regulated in the direct co-culture of breast cancer cells and 
ASCs 
5) CCL5 enhances MMP-9 activity in ASCs but not in MDA MB 231 breast 
cancer cells 
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7. Discussion 
	  
The aim of this study was to clarify how adipose tissue derived stem cells (ASCs) as 
part of the breast cancer microenvironment might be involved in breast cancer 
metastasis. Furthermore, we sought to identify potential molecular targets in this 
interaction that could lead to the development of tumor microenvironment specific 
therapies in breast cancer. 
 
Evidence has been growing over the last decades that the tumor microenvironment is 
significantly involved in tumor progression on all stages, from primary tumor growth to 
development of distant metastases (Albini and Sporn, 2007; Elenbaas and Weinberg, 
2001; Witz, 2008). In this context, cancer associated fibroblasts (CAF), myofibroblasts, 
tumor associated macrophages (TAM), monocytes, as well as bone marrow derived 
progenitor and stem cells have been studied extensively and described in various 
aspects (Olumi et al., 1999; Jeon et al., 2008; Allavena et al., 2008b; Kaplan et al., 
2006). 
 
Furthermore, a variety of bone marrow derived cells have been shown to be involved in 
tumor growth through providing cellular components for neoangiogenesis, supporting 
the vascularization that is necessary for a tumor to grow beyond a certain size (Du et 
al., 2008). The group of Karnoub has investigated specifically the interaction of bone 
marrow derived stem cells and breast cancer cells in primary tumor growth as well as 
the rate of lung metastases in a murine breast cancer model (Karnoub et al., 2007). 
 
Interestingly the role of adipose tissue derived stem cells (ASCs) has not been 
addressed in the context of breast cancer microenvironment and metastasis. With the 
growing evidence for alteration of the tumor microenvironment resembling 
inflammatory processes, we hypothesized that ASCs might represent an important 
source of early multipotent response cells being manipulated by breast cancer cells, 
and thus contribute to creating a reactive environment, for example, by either 
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producing chemoattractant factors that subsequently recruit inflammatory cells or by 
secreting factors that act in a paracrine fashion on breast cancer cells or the 
surrounding microenvironment. 
 
In order to investigate the interaction of ASCs and breast cancer cells, we started to 
evaluate the effect of stem cell conditioned medium on breast cancer cell proliferation 
by exposing human breast cancer MDA MB 231 cells to stem cell conditioned medium 
(SCCM) and compared their growth rate to MDA MB 231 cells in regular growth 
medium.  
 
Similar experiments with various cancer types have been done by other groups (Zhu et 
al., 2009; Ohlsson et al., 2003; Ramasamy et al., 2007) and show an inhibition of 
cancer cell proliferation. However, in these cases, irradiated stem cells, virally 
transfected stem cells, or much higher tumor cell-stem cell ratios had been used for the 
experiments, which might have altered the outcome of these studies.  
 
In contrast to these findings, we (Muehlberg et al., 2009) and other groups (Karnoub et 
al., 2007; Mishra et al., 2008) showed that co-injection of breast cancer cells and 
mesenchymal stem cells from the bone marrow or tissue resident stem cells derived 
from the adipose tissue enhanced tumor growth tremendously in nude mice models. 
The proliferation experiment of the present study confirmed these in vivo observations 
in such a way that we could detect a higher number of MDA MB 231 cells after being 
exposed to SCCM over four days. The first significant difference in cell number was 
observed on day four.  
Furthermore, this experiment was important towards ruling out the possibility that 
proliferation differences within the first 48 hours would affect the final results of the 
invasion assays. 
 
To study the effect of a direct co-culture of ASCs and breast cancer cells on the 
invasive capacity of the tumor cells, several invasion assays have been carried out. We 
chose the murine breast cancer cell line 4T1 and the two human breast cancer cell 
lines MCF-7 and MDA MB 231 that have been characterized for different invasive 
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capacities. In both the 4T1 and the MDA MB 231 co-culture, we could observe an 
increase in invasive cancer cells of 137% and 126% respectively.  
Since the MCF-7 cell line did grow into a colony, we were not able to quantify the visual 
impression of an increased number of invasive tumor cells. However the increase of 
invasive MCF-7 cells when co-seeded with ASCs seemed not to be as dramatic as 
compared to 4T1 and MDA MB 231 cells.  
 
This might imply that the invasion-promoting effect of ASCs becomes more important 
according to the initial invasiveness of the breast cancer cells, although we could not 
confirm this hypothesis due to difficulties in quantification of invasive MCF-7 cells. 
These results are in line with the in vivo studies that have been done by the laboratory 
of Karnoub (Karnoub et al., 2007). 
 
According to the observations described above we focused on MDA MB 231 cells for 
further investigation. Our question was how the ASCs could possibly enhance the 
invasive behavior of breast cancer cells. 
 
In a candidate approach we measured the chemokine CCL5 (RANTES) in the 
supernatants of ASCs, MDA MB 231, and direct co-cultures in a ratio of stem cells to 
tumor cells of 1:2.  
 
Remarkably, a high concentration of CCL5 could only be detected in the direct co-
culture of MDA MB 231 cells with hASCs and was not detectable at all in the 
supernatants of the corresponding single cultures.  
Through further experiments, we concluded by ELISA that humoral tumor derived 
factors secreted by MDA MB 231 cells induce a de novo secretion of CCL5 by ASCs. 
According to different studies (Altman et al., 1997; Azenshtein et al., 2002), epithelial 
cells, immunocompetent cells and tumor cells either constitutionally express CCL5 or 
are stimulated by tumor necrosis factor α (TNFα) and consequently express CCL5 
(Robinson et al., 2002; Balkwill, 2004).  
However, the TNFα level that we measured in the supernatants of MDA MB 231 tissue 
cultures was very low, and experiments where we incubated the supernatants of MDA 
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MB 231 cells with neutralizing antibodies against TNFα before exposing ASCs to the 
tumor conditioned medium did not result in a decrease in CCL5 secretion by ASCs.  
We concluded that either other factors are responsible in this context for the induction 
of CCL5, or the complex interplay between several factors is causing the secretion of 
CCL5.  
Possible ways to identify these mediators are to use shRNA treated MDA MB 231, thus 
knocking down different genes encoding possible mediators, or by screening the 
supernatants of MDA MB 231 cells for active proteins and subsequently characterizing 
those. The group of Glod (Lin et al., 2008b) used an interesting experimental approach 
including mass spectrometry to identify factors secreted by MDA MB 231 cells 
responsible for the chemoattraction of mesenchymal stem cells from the bone marrow 
(MSCs).  
Cyclophilin B and hepatoma-derived growth factor were the two proteins characterized 
for their promigratory effect on MSCs. It would be interesting to see whether these 
factors are also involved in the stimulation of ASCs. 
 
After having identified CCL5 as a de novo secreted chemokine in the interaction of 
ASCs and breast cancer cells, we asked whether CCL5 might be involved in promoting 
the invasion of MDA MB 231 cells. We therefore incubated the direct co-cultures of 
ASCs and MDA MB 231 cells with a neutralizing antibody against CCL5.  
We found that blocking CCL5 completely abolished the invasion-promoting effect of 
ASCs but did not inhibit the intrinsic invasion capacities of MDA MB 231. These in vitro 
findings support the importance of CCL5 for MDA MB 231 metastasis as shown by the 
group of Karnoub (Karnoub et al., 2007). We confirmed with a control IgG antibody that 
only specific blocking of CCL5 was responsible for this observation.  
Interestingly the study of Karnoub et al. (Karnoub et al., 2007) showed in a mouse 
model that systemic application of a neutralizing CCL5 antibody significantly inhibited 
the metastatic spread from the primary tumor site.  
 
Trastuzumab and bevacizumab, two monoclonal antibodies targeting HER-2 and 
VEGF respectively, are already in use in the context of managing metastatic disease in 
breast cancer patients. Women with widespread disease involving multiple 
Discussion	   	  60	  
symptomatic sites especially seem to be better served with an initial systemic 
treatment. However, only five to ten percent of patients with MBC survive five or more 
years. Clinical trials evaluating the benefit of early breast cancer stage patients treated 
with trastuzumab did not show a clear benefit (Mackey et al., 2009).  
Therefore, new molecular targets such as chemokines might help in finding optimal 
combination therapies that finally lead to better control of metastatic dissemination in 
breast cancer patients.  
 
We asked whether MMP-9 might be involved in the interaction of ASCs and MDA MB 
231 cells, and subsequently conducted experiments to measure MMP-9 activity in the 
supernatants of direct ASC - MDA MB 231 co-cultures at different time points and 
found that MMP-9 is upregulated in a time-dependent manner (Fig. 18). 
 
However, it was still not clear which of the two cells or if maybe both were secreting 
MMP-9. It has been shown that MMP-9 is regulated by various factors such as IGF, 
TNFα, TGFβ (Mira et al., 1999; Hagemann et al., 2004) and other factors like the 
chemokine CCL5 (Okita et al., 2005; Chabot et al., 2006), in some cases dependent on 
the Smad-, Ras-, and PI3-kinase-signaling pathway (Stuelten et al., 2005).  
We first wanted to see whether CCL5 is possibly involved in upregulating MMP-9 or 
MMP-2 in either the MDA MB 231 or the ASCs, and therefore checked for the 
expression of the major CCL5 receptor CCR5. 
 
In order to see whether MDA MB 231 cells or ASCs express the main CCL5 receptor 
CCR5, we used RT-PCR and. Interestingly, we found that the expression of CCR5 in 
MDA MB 231 cells was 40.9-fold higher than normal, according to our RT-PCR results. 
The immunostaining revealed that CCR5 was detectable in a more homogenous 
pattern on the cell surfaces of the MDA MB 231 cells as compared to the ASCs, but a 
clear signal was stably detectable in both cell lines, and the no-primary controls were 
negative in all cases.  
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It has been well established that breast cancer cells express CCR5 (Manes et al., 
2003; Zlotnik, 2006), but regarding ASCs we found controversial statements about the 
expression of CCR5 in  mesenchymal stem cells.  
 
The group of Kroeze (Kroeze et al., 2009) found by flow cytometry that mesenchymal 
stem cells from adipose tissue do not express CCR5, whereas the group of Ji (Ji et al., 
2004) showed by PCR, flow cytometry, and immunostaining that CCR5 was expressed 
on rat mesenchymal stem cells derived from the bone marrow, which is in direct 
contradiction to the work of the group of Karnoub (Karnoub et al., 2007) claiming that 
bone marrow derived stem cells did not express CCR5.  
Hence we concluded that surface expression of certain receptors might differ according 
to the origin, passage, and culture conditions of the cell type or applied methodology.  
 
Since the expression of CCR5 on human adipose tissue derived stem cells showed in 
our experiments to be consistently expressed in both RT-PCR and immunostaining, we 
hypothesized that CCL5 might also act in an autocrine fashion on ASCs. 
 
Therefore, we conducted experiments where we stimulated MDA MB 231 cells and 
ASCs for over 48 hours with human recombinant CCL5 at different concentrations 
(Fig.20) and measured the activity of MMP-9 and MMP-2 in the supernatants with 
zymography.  
We found that both cell lines showed slight MMP-9 and strong MMP-2 activity. 
Interestingly, we could only detect an elevated level of MMP-9 activity in the 
supernatants of ASCs when stimulated with CCL5 at a concentration of 100ng/ml, but 
not in MDA MB 231 cells.  
Accordingly we hypothesized that CCL5 is possibly involved in the upregulation of 
MMP-9 in mesenchymal stem cells derived from the adipose tissue. These results 
support the idea that CCL5 plays a role in upregulating MMP-9 in immature dendritic 
cells and T-cells (Chabot et al., 2006; Okita et al., 2005).  
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Further investigation is necessary to clarify the relative importance of CCL-5 induced 
MMP-9 secretion as compared to migration enhancing effects of CCL5. A schematic 
overview of the results of this study is shown in Fig. 22. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It would be interesting now to see whether MDA MB 231 cells also secrete factors that 
attract and mobilize adipose tissue derived stem cells. This seems to be very likely 
according to the findings of the group of Lin (Lin et al., 2008a) and Dwyer (Dwyer et al., 
2007), which showed that bone marrow derived stem cells (BMSC) home to tumor 
sites and described scenarios of BMSC as carriers of therapeutic drugs, astested in 
some in vivo tumor models (Picinich et al., 2007). Nevertheless BMSCs are not as 
easy accessible as ASCs. and the tumor homing capacity of ASCs has been 
investigated by the group of Lamfers (Lamfers et al., 2009; Kucerova et al., 2007), who  
Fig. 22 Schematic overview of aspects in the context of MDA MB 231 breast cancer cells 
(blue) interacting with human adipose tissue derived stem cells (yellow). Red circles 
represent secreted CCL5 (RANTES). 
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showed that ASCs might be an alternative for bone marrow derived stem cells as anti-
cancer drug delivery vehicles. 
 
Taken together, the results of this study suggest that CCL5 might represent an 
interesting target for breast cancer treatment, especially for highly metastatic breast 
cancer subtypes.  
Although bone marrow derived stem cells have been characterized in several studies 
according to their interaction with tumor cells, the study of (Tomiyama et al., 2008) 
indicates that despite a common origin from the mesenchymal germinal sheet,  this 
does not necessarily mean that stem cells from the adipose tissue share complete 
functional identity with bone marrow-derived stem cells.  
Interestingly ASCs also seem to differ in their ability to promote angiogenic recovery 
and were subsequently found to differ in their tube formation and 
matrixmetalloproteinase expressing profile (Kim et al., 2007) in such a way that blood 
flow recovery in a hindlimb ischemia model of nude mice was stronger when ASCs 
were applied.  
Furthermore, we hypothesize that the role of tissue resident stem cells needs to be 
reconsidered for developing a more complete concept of breast cancer pathogenesis 
that includes the role of the huge variety of cells composing the tumor stroma, which 
crucially contributes to reorganizing the tumor microenvironment, creating the 
inflammatory or desmoplastic stroma which permits tumor growth over small sizes and 
finally enables tumor cells to metastasize.  
 
Despite the growing evidence for a metastasis promoting function of CCL5, the exact 
role of CCL5 in breast cancer still remains elusive since the group of Jayasinghe 
(Jayasinghe et al., 2008) has shown that tumor derived CCL5 does not affect tumor 
growth and metastasis by using interference RNA to inhibit CCL5 translation in the 
highly metastatic murine breast cancer cell line 4T1 and by overexpressing CCL5 in a 
less metastatic murine breast cancer cell line 168.  
Despite the methodological problems that come along with this approach and the 
intrinsic difference between metastasis and tumorgrowth subclones, this study 
supports the significance of host derived CCL5 in the context of breast cancer 
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progression. To prove this conclusion, CCL5 knockout mouse might provide important 
insights.  
 
To summarize the present study, we identified CCL5 (RANTES) as a potential 
mediator in the interaction of human adipose tissue derived stem cells and breast 
cancer cells in tumor cell invasion and characterized its effect on 
Matrixmetalloproteinase 9 activity, and conclude that CCL5 or its receptor CCR5 might 
represent potential targets for mammary cancer progression, especially in highly 
invasive cases. 
 
Cancer remains one of the most complex and challenging diseases in human beings, 
not only because of the myriad of potential mechanisms that lead to the malignant 
transformation on the cellular level, but also because of the enormous involvement of 
local and systemic factors that differ in every human individual. Finding therapies for 
cancer requires the investigation of each single parameter in this multistep process in 
order to define targets that can be focused on and thus promise a cure, longer lifetime, 
or at least an increase in quality of life for patients suffering from cancer 
7.1 Summary of discussion 
Breast cancer is the cancer with the highest incidence among women. Although tumor 
evolution and progression has been well studied in the past decades on the cellular 
level of cancer cells, the interaction of breast cancer cells with surrounding non-
tumorigenic tissue still leaves many questions unanswered. 
Immunomodulatory cells like macrophages, monocytes, and T-cells, as well as other 
bone marrow derived cells, have been characterized in many aspects of their 
involvement in breast cancer development and metastasis. Nevertheless, the specific 
role of tissue resident stem cells has not been investigated yet. 
It has been shown that the tumor microenvironment not only provides the cellular and 
extracellular material for primary tumor growth, but also plays a pivotal role in tumor 
metastasis. 
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Therefore, we sought to elucidate whether and how adipose tissue derived stem cells 
might contribute to breast cancer cell invasion, and which mediators could be involved. 
After observing that adipose tissue derived stem cells enhance tumor invasion in vitro 
by roughly doubling the amount of invasive cells, we could identify CCL5 (RANTES) as 
an important mediator in this process. 
Interestingly we found that human breast cancer cells MDA MB 231 induce a de novo 
secretion of CCL5 by secreted factors, which are still to be identified. 
Furthermore, we found that Matrixmetalloproteinase 9 is upregulated in the context of 
breast cancer cells, interacting directly with adipose tissue derived stem cells. We also 
showed that hASCs produce more active MMP-9 when being stimulated with CCL5. 
We conclude that adipose tissue derived stem cells might represent an important factor 
in breast cancer metastasis for microenvironment-targeted therapies. 
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12. Addendum 
 
12.1. Figures 
Figure 1  (p.15) Chemical structure of CCL5  
Figure 2  (p. 24) a) Liposuction 
   b) Human fat tissue after digestion 
Figure 3  (p. 25) Human adipose tissue derived stem cells in culture 
Figure 4  (p. 31) a) Insert and 24-well plate  
 b) Schematic illustration of invasion assay 
Figure 5  (p. 36) Flowchart of experiments 
Figure 6  (p. 38) Proliferation Assay 
Figure 7  (p. 40) Invasion Assay 4T1 
Figure 8  (p. 41) Graph Invasion Assay 4T1 
Figure 9  (p. 42) Invasion Assay MCF-7 
Figure 10  (p. 43) Invasion Assay MDA MB 231 
Figure 11  (p. 44) Graph Invasion Assay MDA MB 231 
Figure 12  (p. 45) Direct co-culture of MDA MB 231 and hASCs 
Figure 13  (p. 46) Direct co-culture of MCF-7 and hASCs 
Figure 14  (p. 47) a) Graph CCL5 in MDA MB 231 and  
  hASCs co-culture  
   b) Graph CCL5 in MCF-7 and hASCs co-culture 
Figure 15  (p. 48) a) Graph CCL5 kinetics MDA MB 231 and
 hASCs co-culture  
   b) CCL5 Control ELISA 
Figure 16  (p. 49) Scheme of cross conditioning 
Figure 17  (p. 50) Immunostaining (MDA MB 231) for CCR5.  
Figure 18  (p. 51)  Graph mRNA expression of CCR5 in MDA MB 231  
   and hASCs and Immunostaining (hASCs) for CCR5 
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Figure 19  (p. 52) MMP-9 activity in MDA MB 231 and hASCs  
  co-culture 
Figure 20  (p. 53) Graph MMP-9 activity in MDA MB 231 and  
  hASCs co-culture 
Figure 21  (p. 54) MMP-9 and MMP-2 activity of MDA MB 231 and  
  hASCs after stimulation with recombinant human  
  CCL5 
Figure 22  (p. 62) Schematic overview results 
 
12.2. Tables 
Table 1 (p. 18) Cell types 
Table 2 (p. 33) cDNA reaction mix 
 
